Etudes sponsorisées interventionnelles en cours:
- PEARLS: A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy.
- Intr@pid: A Phase II, Multicenter, Randomized, Open-Label, Controlled Study of M7824 versus Pembrolizumab as a First-line Treatment in Patients with PD-L1 Expressing Advanced Nonsmall Cell Lung Cancer.
Etudes sponsorisées non interventionnelles en cours:
- BEPACT Lung: Impact of Patient Characteristics on pneumo-oncologists NSCLC systemic treatment decision in Belgium: A cross-sectional study.
Etudes académiques non interventionnelles en cours:
- ELCWP: Cardiovascular morbidities and lung cancer treatment: a prospective registry.